Zealand Pharma A/S American Depositary Shares
ZEAL
ZEAL was delisted on the 29th of September, 2022.
14 hedge funds and large institutions have $63.4M invested in Zealand Pharma A/S American Depositary Shares in 2020 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 2 closing their positions.
6% more capital invested
Capital invested by funds: $60.1M → $63.4M (+$3.33M)
13% less funds holding
Funds holding: 16 → 14 (-2)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$181K |
| 2 |
JP Morgan Chase
New York
|
+$26.4K |
| 3 |
Morgan Stanley
New York
|
+$12.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.33M |
| 2 |
Jane Street
New York
|
-$361K |
| 3 |
Rockefeller Capital Management
New York
|
-$175K |
| 4 |
Renaissance Technologies
New York
|
-$101K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.34K |
ZEAL Hedge Fund Activity: Q3 2020 in Review
14 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Zealand Pharma A/S American Depositary Shares (ZEAL) for Q3 2020, worth a combined $63.4M — up 5.5% from $60.1M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ZEAL and 0 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was Farallon Capital Management, adding an estimated $181K. The largest seller was Wellington Management Group, cutting an estimated $1.33M.
- 14 institutional investors held Zealand Pharma A/S American Depositary Shares (ZEAL) as of Q3 2020, down from 16 in Q2 2020.
- Funds reported $63.4M of Zealand Pharma A/S American Depositary Shares stock for Q3 2020, up 5.5% quarter-over-quarter.
- 0 funds opened new Zealand Pharma A/S American Depositary Shares positions in Q3 2020 and 2 closed out, a net change of -2 holders.
- The largest Zealand Pharma A/S American Depositary Shares buyer in Q3 2020 was Farallon Capital Management, an estimated $181K added.
- The largest Zealand Pharma A/S American Depositary Shares seller in Q3 2020 was Wellington Management Group, an estimated $1.33M sold.
Based on aggregated 13F filings for Q3 2020.